Clinical trials: Metabolism Disorder
- Condition Metabolism Disorder
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy Participants
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.
- Trial name
- NCT07723833
- Testing
- Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Satiety, Appetite
A Study of NatureU Burn on Satiety in Healthy Adults
This single-center, single-blind, non-randomized crossover exploratory study evaluated the short-term effects of NatureU Burn on postprandial satiety in healthy adults.
- Conditions
- Satiety, Appetite, Food Intake, Fat Disorder
- Trial name
- NUBURN (NCT07597382)
- Testing
- Glucose Reference Food, NatureU Burn Plus Glucose
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- OmniSolutions Laboratory Holdings Limited
Healthy, Type 2 Diabetes Mellitus (T2D)
A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants
The purpose of this study is to evaluate how well LY3549492 is tolerated and what side effects may occur in Japanese participants with Type 2 Diabetes Mellitus (T2D) and healthy Japanese participants.
- Trial name
- NCT06869018
- Testing
- LY3549492
- Where
- 4 sites in Japan
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Disorders of Sphingolipid Metabolism, Healthy Volunteers
Excretion Balance, Pharmacokinetics, and Metabolism Following of [14C]-Venglustat Administration in Healthy Male Subjects
Primary Objectives: To determine the excretion balance and systemic exposure of radioactivity after oral administration of [14C]-venglustat.
- Trial name
- NCT05238714
- Testing
- venglustat
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Weight Loss, Metabolic Syndrome
Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes.
- Conditions
- Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity
- Trial name
- NCT05874635
- Testing
- Continuous Glucose Monitor Device
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Signos Inc
Weight Loss, Metabolic Syndrome
Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform
Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence…
- Conditions
- Weight Loss, Metabolic Syndrome, Pre-diabetes, Central Obesity
- Trial name
- NCT05121844
- Testing
- Continuous Glucose Monitor Device
- Where
- United States
- Volunteers
- 31,187 people, healthy volunteers welcome
- Sponsor
- Signos Inc
Diabetes Type 2, Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.
- Conditions
- Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- SURPASS-CN-INS (NCT05691712)
- Testing
- Tirzepatide
- Where
- 25 sites in China
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Cardiovascular Diseases, Lipid Metabolism Disorders
"Perfect Heartio" Drink and Cardiovascular Health
Noncommunicable diseases (NCDs) such as type 2 diabetes (T2D) and cardiovascular disease (CVD) account for more deaths globally than any other condition. In 2018, the WHO reported that NCDs accounted for 71% of global deaths.
- Trial name
- NCT07048158
- Testing
- Perfect Heartio Drink
- Where
- Malaysia
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- The Perfect Series Sdn Bhd
Glucose Metabolism Disorders, Health Behavior
Relationship Between Individual Effect of Diet on Postprandial Glycemia and Gut Microbiome Profile in Healthy Subjects
When all the food we eat is digested, it will increase blood glucose. Two people can have different glucose blood levels to the same food and one reason can be bacteria live in our gut.
- Conditions
- Glucose Metabolism Disorders, Health Behavior, Diabetes, Metabolic Disease
- Trial name
- NCT06051318
- Testing
- Standardized breakfast A, Standardized breakfast B
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- BiomeHub Biotechnology Company
Chronic Diabetic Foot Ulcers
Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer
A PHASE 2a, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE ESCALATING STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TOPICALLY APPLIED BISPHOSPHOCIN NU-3 GEL TO CLINICALLY NONINFECTED CHRONIC DIABETIC FOOT…
- Trial name
- NCT05276401
- Testing
- 5% Bisphosphocin Topical Gel, 10% Bisphosphocin Topical Gel
- Where
- 5 sites in United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Lakewood-Amedex Inc
Pre Diabetes, Impaired Glucose Tolerance
Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control
This 12 week placebo-controlled study evaluates the efficacy and safety of E. hallii supplementation.
- Conditions
- Pre Diabetes, Impaired Glucose Tolerance, Insulin Sensitivity, Insulin Resistance
- Trial name
- NCT04529473
- Testing
- Eubacterium hallii
- Where
- 3 sites in United States, Ireland and 1 more
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Atlantia Food Clinical Trials
Fat Disorder
Non-invasive Lipolysis and Improvement of Muscle Tone in Upper Arms
This study will evaluate the clinical efficacy and safety of the BTL-899 device for changes in subcutaneous fat tissue and muscle tissue of arms. The study is a prospective multi-center open-label single-arm study.
- Trial name
- NCT04596241
- Testing
- BTL-899
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Fat Disorder
Non-invasive Lipolysis and Improvement of Muscle Tone in Inner Thighs
This study will evaluate the clinical efficacy and safety of the BTL-899 device for changes in subcutaneous fat tissue and muscle tissue of inner thighs. The study is a prospective multi-center open-label single-arm study.
- Trial name
- NCT04596228
- Testing
- BTL-899
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Fat Disorder, Fat Redistribution
Effect of Tecartherapy in the Treatment of Localized Fat and Sagging Abdominal Skin - Clinical and Experimental Study
The excess of localized fat causes changes in the body contour and consequently changes in the properties of the skin and in the connective tissue, providing sagging skin.
- Trial name
- Tecarterapy (NCT05020054)
- Testing
- Tecartherapy Intervention
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Indústria Brasileira Equipamentos Médicos - IBRAMED
Fat Disorder
Non-invasive Cooling of Subcutaneous Fat
The purpose of this study is to evaluate a non-invasive cooling device to determine if cold exposure will consistently result in a reduction of subcutaneous fat.
- Trial name
- NCT00762307
- Testing
- Zeltiq Dermal Cooling Device
- Where
- 4 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Fat Disorder
Eon™ FR Clinical Study Protocol 1064
This study evaluates the treatment of subjects with the eon™ FR 1064 nm device in a single session to thermally induce apoptosis in adipose tissue.
- Trial name
- NCT03898830
- Testing
- eon™ FR 1064 nm device
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dominion Aesthetic Technologies, Inc.
Diabetes Mellitus, Glucose Metabolism Disorders
Effects of Simulated Passive Jogging Device on Glucose Homeostasis, Muscle Strength and Endurance
Physical Inactivity and excessive sedentary behavior are risk factors for diabetes and cardiovascular disease. Movement is important for overall health.
- Conditions
- Diabetes Mellitus, Glucose Metabolism Disorders, Physical Activity
- Trial name
- NCT03550105
- Testing
- Gentle Jogger
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sackner Wellness Products LLC
Metabolism and Nutrition Disorder, Obesity
Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity
The study is testing a new medicine for weight control in people with overweight or obesity. The aim of the study is to find out how safe the study medicine is and how it works in the body.
- Trial name
- NCT03661879
- Testing
- NNC9204-1706
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Fat Disorder
SlimShape Device for Abdominal Fat and Circumference Reduction
Prospective, one-arm, baseline-controlled, clinical study for the evaluation of the SlimShape device for non-invasive abdominal fat and circumference reduction.
- Trial name
- NCT02999763
- Testing
- SlimShape
- Where
- 4 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Syneron Medical
Glucose Metabolism Disorders
Effects of Deepure(Pu-erh Tea Extract) on Glycemic Control
This is a randomized, controlled, cross-over study on the effects of consumption of Deepure puerh tea extract (PTE) on glucose tolerance and metabolic markers.
- Trial name
- NCT03613688
- Testing
- Deepure
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Tasly Pharmaceuticals, Inc.